Market Place
Sourcing Support
Acadia Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)
15 Nov 2024 //
BUSINESSWIRE
Acadia makes $100M profit from $150M pediatric voucher sale
06 Nov 2024 //
FIERCE BIOTECH
Acadia Pharmaceuticals Reports Q3 2024 Results & Overview
06 Nov 2024 //
BUSINESSWIRE
Acadia Sells Rare Pediatric Disease Priority Review Voucher for $150M
05 Nov 2024 //
BUSINESSWIRE
Acadia Pharmaceuticals To Announce Q3 Results On November 6
17 Oct 2024 //
BUSINESSWIRE
Acadia Announces Health Canada Approval Of Daybue For Rett Syndrome
16 Oct 2024 //
BUSINESSWIRE
Acadia Pharma Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
08 Oct 2024 //
BUSINESSWIRE
Acadia Pharmaceuticals Reports Inducement Grants
26 Sep 2024 //
BUSINESSWIRE
Catherine Owen Adams New CEO Of Acadia Pharmaceuticals
23 Sep 2024 //
BUSINESSWIRE
Axcelead Enters Agreement With Acadia Pharmaceuticals
19 Sep 2024 //
BUSINESSWIRE
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
28 Aug 2024 //
BUSINESSWIRE
Acadia Partners With Ryan Reynolds For Parkinson`s Campaign
14 Aug 2024 //
FIERCE PHARMA
Acadia Pharmaceuticals To Participate In Canaccord Genuity Growth Conference
07 Aug 2024 //
BUSINESSWIRE
Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results
06 Aug 2024 //
BUSINESSWIRE
Acadia Pharmaceuticals To Report Q2 Results On August 6
24 Jul 2024 //
BUSINESSWIRE
DAYBUE™ Long-Term Data For Rett Syndrome Published In Med
18 Jul 2024 //
BUSINESSWIRE
Acadia Presents DAYBUE™ Real-World Evidence In Rett Syndrome At IRSF Meeting
18 Jun 2024 //
BUSINESSWIRE
Acadia Reports Inducement Grants Under Nasdaq 5635(c)(4)
17 May 2024 //
BUSINESSWIRE
Acadia adds awareness-raising docuseries to Rett syndrome site
15 May 2024 //
FIERCE PHARMA
Acadia Launches Magnolia`s Guide Documentary Series On Rett Syndrome
15 May 2024 //
BUSINESSWIRE
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
09 May 2024 //
BUSINESSWIRE
Acadia Pharmaceuticals: Q1 2024 Financials, Operations
08 May 2024 //
BUSINESSWIRE
Acadia Announces Inaugural Rett Sibling Scholarship Winners
29 Apr 2024 //
BUSINESSWIRE
Acadia to Report Q1 2024 Results on May 8
24 Apr 2024 //
BUSINESSWIRE
Acadia`s Trofinetide NDS For Rett Accepted, Priority Review
22 Apr 2024 //
BUSINESSWIRE
Acadia Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)
19 Apr 2024 //
BUSINESSWIRE
Acadia Appoints Elizabeth as Executive VP, Head of Research and Development
02 Apr 2024 //
BUSINESSWIRE
Acadia to Participate in the 23rd Annual Needham Virtual Healthcare Conference
01 Apr 2024 //
BUSINESSWIRE
Acadia Acquires Three Comprehensive Treatment Centers in North Carolina
28 Mar 2024 //
BUSINESSWIRE
Acadia Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
15 Mar 2024 //
BUSINESSWIRE
Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day
13 Mar 2024 //
BUSINESSWIRE
Acadia to stop trials of antipsychotic drug after it fails schizophrenia study
12 Mar 2024 //
REUTERS
Acadia to Participate in TD Cowen’s 44th Annual Health Care Conference
29 Feb 2024 //
PRESS RELEASE
Acadia Pharma Reports Fourth Quarter and Full Year 2023 Financial Results
27 Feb 2024 //
BUSINESSWIRE
Acadia Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
21 Feb 2024 //
BUSINESSWIRE
Acadia to Announce Fourth Quarter and Full Year 2023 Financial Results
13 Feb 2024 //
BUSINESSWIRE
Acadia Announces Additions to Executive Team
30 Jan 2024 //
BUSINESSWIRE
Acadia Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19 Jan 2024 //
BUSINESSWIRE
Acadia Announces the Passing of Former President Srdjan (Serge) Stankovic
18 Jan 2024 //
BUSINESSWIRE
Acadia to Present at the 42nd Annual J.P. Morgan Healthcare Conference
21 Dec 2023 //
BUSINESSWIRE
Acadia Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18 Dec 2023 //
BUSINESSWIRE
Acadia Rises 35% on Positive Patent Ruling for Nuplazid
14 Dec 2023 //
NASDAQ
Delaware Federal District Court Rules in Favor of Acadia in NUPLAZID
13 Dec 2023 //
PRESS RELEASE
Acadia Pharmaceuticals Initiates Pivotal Phase 3 Study of Carbetocin (ACP-101)
30 Nov 2023 //
BUSINESSWIRE
Acadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204
27 Nov 2023 //
BUSINESSWIRE
Acadia Pharmaceuticals Announces Change in Research and Development Leadership
21 Nov 2023 //
BUSINESSWIRE
Acadia Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
14 Nov 2023 //
BUSINESSWIRE
Acadia Reports Third Quarter 2023 Financial Results and Operating Overview
02 Nov 2023 //
BUSINESSWIRE
Acadia to Participate in the Guggenheim Securities 5th Annual Conference
31 Oct 2023 //
BUSINESSWIRE
Acadia Pharmaceuticals Announces the Rett Sibling Scholarship Program
23 Oct 2023 //
BUSINESSWIRE
Acadia Pharma to Announce Third Quarter Financial Results on November 2, 2023
19 Oct 2023 //
BUSINESSWIRE
Acadia Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18 Oct 2023 //
BUSINESSWIRE
Why Acadia Pharmaceuticals Stock Is Rising Today
10 Oct 2023 //
FOOL
Acadia Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
22 Sep 2023 //
BUSINESSWIRE
Acadia Pharmaceuticals Appoints Albert Kildani as Senior Vice President
19 Sep 2023 //
BUSINESSWIRE
Acadia Pharmaceuticals Announces Label Update for NUPLAZID® (pimavanserin)
18 Sep 2023 //
PRESS RELEASE
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
30 Aug 2023 //
BUSINESSWIRE
Acadia Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
14 Aug 2023 //
BUSINESSWIRE
Acadia Pharmaceuticals Reports Second Quarter 2023 Financial Results
02 Aug 2023 //
BUSINESSWIRE
Acadia Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Aug 2023 //
BUSINESSWIRE
